FDA Approves United Therapeutics' LungFX Device for Centralized Ex Vivo Lung Perfusion — United Therapeutics Corporation

Event summary

United Therapeutics' LungFX device received FDA premarket approval for centralized ex vivo lung perfusion (EVLP) on June 29, 2026.
The device is designed to assess and potentially make suitable for transplant over 80% of donor lungs currently deemed unsuitable.
Lung Bioengineering, a subsidiary of United Therapeutics, has performed 1,100 EVLP procedures with other approved devices, resulting in 600 successful transplants.
LungFX is the first EVLP device approved specifically for use in centralized facilities, expanding access without requiring hospitals to build their own capabilities.

The big picture

The FDA approval of LungFX underscores the growing emphasis on extending the viability of donor organs through advanced ex vivo technologies. This aligns with broader industry trends toward centralized organ assessment facilities, reducing waste in the transplant process. United Therapeutics' strategic focus on creating an unlimited supply of transplantable organs positions it as a key player in the evolving landscape of organ transplantation and bioengineering.

What we're watching

Adoption Pace: The pace at which transplant programs integrate LungFX into their workflows, particularly those without existing EVLP capabilities.
Clinical Outcomes: Whether longer-term recipient survival and graft function data will validate the device's effectiveness beyond the initial 12-month study period.
Market Expansion: How United Therapeutics leverages this approval to expand its platform for advancing new technologies designed to enhance donor lung function.